Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.

Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger M, Kaufmann PA, Hermanns T, Burger IA.

World J Urol. 2018 Jul 20. doi: 10.1007/s00345-018-2408-2. [Epub ahead of print] Review.

PMID:
30030659
2.

[Role of stereotactic body radiation therapy for unresected pancreatic cancer].

Heitmann J, Guckenberger M.

Strahlenther Onkol. 2018 Jul 9. doi: 10.1007/s00066-018-1331-1. [Epub ahead of print] German. No abstract available.

PMID:
29987339
3.

Correspondence on Rajyaguru et al.

Boda-Heggemann J, Gkika E, Andratschke N, Blanck O, Guckenberger M, Lohr F, Brunner TB.

J Clin Oncol. 2018 Jun 26:JCO2018781542. doi: 10.1200/JCO.2018.78.1542. [Epub ahead of print] No abstract available.

PMID:
29945524
4.

The evolution and rise of stereotactic body radiotherapy (SBRT) for spinal metastases.

Vellayappan BA, Chao ST, Foote M, Guckenberger M, Redmond KJ, Chang EL, Mayr NA, Sahgal A, Lo SS.

Expert Rev Anticancer Ther. 2018 Jul 3:1-14. doi: 10.1080/14737140.2018.1493381. [Epub ahead of print]

PMID:
29940802
5.

Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.

Britschgi C, Riesterer O, Burger IA, Guckenberger M, Curioni-Fontecedro A.

Radiat Oncol. 2018 May 31;13(1):102. doi: 10.1186/s13014-018-1049-3.

6.

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Hölscher T, Wust P, Ganswindt U, Baur ADJ, Zöphel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C.

Radiat Oncol. 2018 May 11;13(1):90. doi: 10.1186/s13014-018-1047-5. Review.

7.

Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria.

Alongi F, Mazzola R, Figlia V, Guckenberger M.

Tumori. 2018 Apr 1:300891618766820. doi: 10.1177/0300891618766820. [Epub ahead of print]

PMID:
29714665
8.

Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.

Finazzi T, Rordorf T, Ikenberg K, Huber GF, Guckenberger M, Garcia Schueler HI.

BMC Cancer. 2018 Apr 6;18(1):395. doi: 10.1186/s12885-018-4295-8.

9.

Perspectives on oligometastasis: challenges and opportunities.

Heitmann J, Guckenberger M.

J Thorac Dis. 2018 Jan;10(1):113-117. doi: 10.21037/jtd.2017.12.77. No abstract available.

10.

Population Description and Clinical Response Assessment for Spinal Metastases: Part 2 of the SPIne Response Assessment in Neuro-Oncology (SPINO) Group Report.

Laufer I, Lo SS, Chang EL, Sheehan J, Guckenberger M, Sohn MJ, Ryu S, Foote M, Muacevic A, Soltys SG, Chao S, Myrehaug S, Gerszten PC, Lis E, Maralani P, Bilsky M, Fisher C, Rhines L, Verlaan JJ, Schiff D, Fehlings MG, Ma L, Chang S, Parelukar WR, Vogelbaum MA, Sahgal A.

Neuro Oncol. 2018 Mar 24. doi: 10.1093/neuonc/noy047. [Epub ahead of print]

PMID:
29590465
11.

Histopathological Findings After Reirradiation Compared to First Irradiation of Spinal Bone Metastases With Stereotactic Body Radiotherapy: A Cohort Study.

Foerster R, Cho BCJ, Fahim DK, Gerszten PC, Flickinger JC, Grills IS, Jawad MS, Kersh CR, Létourneau D, Mantel F, Sahgal A, Shin JH, Winey BA, Guckenberger M.

Neurosurgery. 2018 Mar 14. doi: 10.1093/neuros/nyy059. [Epub ahead of print]

PMID:
29547929
12.

The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.

Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Guckenberger M, Hildebrandt G, Klement RJ, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Habermehl D.

BMC Cancer. 2018 Mar 13;18(1):283. doi: 10.1186/s12885-018-4191-2.

13.

Influence of inter-observer delineation variability on radiomics stability in different tumor sites.

Pavic M, Bogowicz M, Würms X, Glatz S, Finazzi T, Riesterer O, Roesch J, Rudofsky L, Friess M, Veit-Haibach P, Huellner M, Opitz I, Weder W, Frauenfelder T, Guckenberger M, Tanadini-Lang S.

Acta Oncol. 2018 Mar 7:1-5. doi: 10.1080/0284186X.2018.1445283. [Epub ahead of print]

PMID:
29513054
14.

Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy.

Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Eich HC, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl KH, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Guckenberger M.

Radiother Oncol. 2018 May;127(2):246-252. doi: 10.1016/j.radonc.2018.02.016. Epub 2018 Mar 3.

PMID:
29510865
15.

Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study.

Guckenberger M, Sweeney RA, Hawkins M, Belderbos J, Andratschke N, Ahmed M, Madani I, Mantel F, Steigerwald S, Flentje M.

Cancer. 2018 May 1;124(9):2001-2009. doi: 10.1002/cncr.31294. Epub 2018 Mar 2.

PMID:
29499073
16.

Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study.

Leijenaar RT, Bogowicz M, Jochems A, Hoebers FJ, Wesseling FW, Huang SH, Chan B, Waldron JN, O'Sullivan B, Rietveld D, Leemans CR, Brakenhoff RH, Riesterer O, Tanadini-Lang S, Guckenberger M, Ikenberg K, Lambin P.

Br J Radiol. 2018 Jun;91(1086):20170498. doi: 10.1259/bjr.20170498. Epub 2018 Mar 22.

PMID:
29451412
17.

Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer.

Tanadini-Lang S, Bogowicz M, Veit-Haibach P, Huellner M, Pauli C, Shukla V, Guckenberger M, Riesterer O.

Anticancer Res. 2018 Feb;38(2):685-690.

18.

Optimization of combined proton-photon treatments.

Unkelbach J, Bangert M, De Amorim Bernstein K, Andratschke N, Guckenberger M.

Radiother Oncol. 2018 Jan 19. pii: S0167-8140(18)30021-5. doi: 10.1016/j.radonc.2017.12.031. [Epub ahead of print]

PMID:
29370987
19.

Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations.

Nieder C, Gaspar LE, Ruysscher D, Guckenberger M, Mehta MP, Rusthoven CG, Sahgal A, Gkika E.

Strahlenther Onkol. 2018 May;194(5):365-374. doi: 10.1007/s00066-018-1266-6. Epub 2018 Jan 23.

PMID:
29362835
20.

Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study.

Basler L, Andratschke N, Ehrbar S, Guckenberger M, Tanadini-Lang S.

Radiat Oncol. 2018 Jan 22;13(1):10. doi: 10.1186/s13014-018-0952-y.

21.

Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study.

Nguyen TK, Senan S, Bradley JD, Franks K, Giuliani M, Guckenberger M, Landis M, Loo BW Jr, Louie AV, Onishi H, Schmidt H, Timmerman R, Videtic GMM, Palma DA.

Pract Radiat Oncol. 2018 Mar - Apr;8(2):e71-e78. doi: 10.1016/j.prro.2017.10.008. Epub 2017 Dec 30.

PMID:
29291965
22.

Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy".

Hoerner-Rieber J, Duma M, Blanck O, Hildebrandt G, Wittig A, Lohaus F, Flentje M, Mantel F, Krempien R, Eble MJ, Kahl KH, Boda-Heggemann J, Rieken S, Guckenberger M.

J Thorac Dis. 2017 Nov;9(11):4512-4522. doi: 10.21037/jtd.2017.10.108.

23.

[Which patients with localized prostate cancer benefit from which local procedure and what does "benefit" mean in prostate cancer?]

Kroeze S, Fritz C, Guckenberger M.

Strahlenther Onkol. 2018 Feb;194(2):174-177. doi: 10.1007/s00066-017-1243-5. German. No abstract available.

PMID:
29264623
24.

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.

Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P.

Cancer Res. 2018 Feb 15;78(4):1031-1043. doi: 10.1158/0008-5472.CAN-17-1788. Epub 2017 Dec 8.

PMID:
29222400
25.

Second re-irradiation: a narrative review of the available clinical data.

Nieder C, Langendijk JA, Guckenberger M, Grosu AL.

Acta Oncol. 2018 Mar;57(3):305-310. doi: 10.1080/0284186X.2017.1409433. Epub 2017 Nov 30.

PMID:
29187033
26.

Unconscious physiological response of healthy volunteers to dynamic respiration-synchronized couch motion.

Jöhl A, Bogowicz M, Ehrbar S, Guckenberger M, Klöck S, Meboldt M, Riesterer O, Zeilinger M, Schmid Daners M, Tanadini-Lang S.

Radiat Oncol. 2017 Nov 28;12(1):189. doi: 10.1186/s13014-017-0925-6.

27.

Short interactive workshops reduce variability in contouring treatment volumes for spine stereotactic body radiation therapy: Experience with the ESTRO FALCON programme and EduCase™ training tool.

De Bari B, Dahele M, Palmu M, Kaylor S, Schiappacasse L, Guckenberger M; ESTRO FALCON core.

Radiother Oncol. 2018 Apr;127(1):150-153. doi: 10.1016/j.radonc.2017.10.038. Epub 2017 Nov 20.

PMID:
29169657
28.

Developing an Integrative Treatment Program for Cancer-Related Fatigue Using Stakeholder Engagement - A Qualitative Study.

Canella C, Mikolasek M, Rostock M, Beyer J, Guckenberger M, Jenewein J, Linka E, Six C, Stoll S, Stupp R, Witt CM.

Integr Cancer Ther. 2017 Nov 1:1534735417740629. doi: 10.1177/1534735417740629. [Epub ahead of print]

PMID:
29161912
29.

Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.

Bogowicz M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, Pruschy M, Studer G, Unkelbach J, Guckenberger M, Konukoglu E, Lambin P.

Radiother Oncol. 2017 Dec;125(3):385-391. doi: 10.1016/j.radonc.2017.10.023. Epub 2017 Nov 6.

PMID:
29122358
30.

Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer.

Karava K, Ehrbar S, Riesterer O, Roesch J, Glatz S, Klöck S, Guckenberger M, Tanadini-Lang S.

Radiat Oncol. 2017 Nov 9;12(1):175. doi: 10.1186/s13014-017-0906-9.

31.

Correction to: Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: a comparison to the RTOG 0933 trial.

Krayenbuehl J, Di Martino M, Guckenberger M, Andratschke N.

Radiat Oncol. 2017 Nov 8;12(1):173. doi: 10.1186/s13014-017-0901-1.

32.

Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.

Kranzbühler B, Nagel H, Becker AS, Müller J, Huellner M, Stolzmann P, Muehlematter U, Guckenberger M, Kaufmann PA, Eberli D, Burger IA.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):20-30. doi: 10.1007/s00259-017-3850-x. Epub 2017 Oct 14.

PMID:
29032394
33.

Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: a comparison to the RTOG 0933 trial.

Krayenbuehl J, Di Martino M, Guckenberger M, Andratschke N.

Radiat Oncol. 2017 Oct 2;12(1):161. doi: 10.1186/s13014-017-0896-7.

34.

[Stereotactic Body Radiotherapy for Early Stage NSCLC - What Is the Evidence?]

Guckenberger M.

Zentralbl Chir. 2017 Sep;142(S 01):S17-S25. doi: 10.1055/s-0043-117177. Epub 2017 Sep 28. German.

PMID:
28958106
35.

Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy.

Unkelbach J, Papp D, Gaddy MR, Andratschke N, Hong T, Guckenberger M.

Radiother Oncol. 2017 Nov;125(2):357-364. doi: 10.1016/j.radonc.2017.09.003. Epub 2017 Sep 23.

PMID:
28951010
36.

Comparison of multi-leaf collimator tracking and treatment-couch tracking during stereotactic body radiation therapy of prostate cancer.

Ehrbar S, Schmid S, Jöhl A, Klöck S, Guckenberger M, Riesterer O, Tanadini-Lang S.

Radiother Oncol. 2017 Dec;125(3):445-452. doi: 10.1016/j.radonc.2017.08.035. Epub 2017 Sep 18.

PMID:
28935181
37.

Time for standardization of SBRT planning through large scale clinical data and guideline-based approaches.

Moustakis C, Blanck O, Ebrahimi F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C, Alheit H, Blank H, Nestle U, Wiehle R, Kornhuber C, Ostheimer C, Petersen C, Pollul G, Baus W, Altenstein G, Beckers E, Jurianz K, Sterzing F, Kretschmer M, Seegenschmiedt H, Maass T, Droege S, Wolf U, Schoeffler J, Haverkamp U, Eich H, Guckenberger M.

Strahlenther Onkol. 2017 Dec;193(12):1068-1069. doi: 10.1007/s00066-017-1216-8. Epub 2017 Sep 15. No abstract available.

PMID:
28916902
38.

Risk for surgical complications after previous stereotactic body radiotherapy of the spine.

Roesch J, Cho JBC, Fahim DK, Gerszten PC, Flickinger JC, Grills IS, Jawad M, Kersh R, Letourneau D, Mantel F, Sahgal A, Shin JH, Winey B, Guckenberger M.

Radiat Oncol. 2017 Sep 11;12(1):153. doi: 10.1186/s13014-017-0887-8.

39.

Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma.

Bogowicz M, Riesterer O, Stark LS, Studer G, Unkelbach J, Guckenberger M, Tanadini-Lang S.

Acta Oncol. 2017 Nov;56(11):1531-1536. doi: 10.1080/0284186X.2017.1346382. Epub 2017 Aug 18.

40.

[German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].

Müller AC, van Oorschot B, Micke O, Guckenberger M.

Strahlenther Onkol. 2018 Jan;194(1):1-8. doi: 10.1007/s00066-017-1185-y. Epub 2017 Aug 17. Review. German.

PMID:
28819766
42.

Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.

Bogowicz M, Riesterer O, Ikenberg K, Stieb S, Moch H, Studer G, Guckenberger M, Tanadini-Lang S.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):921-928. doi: 10.1016/j.ijrobp.2017.06.002. Epub 2017 Jun 15.

PMID:
28807534
43.

The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.

Sharma A, Broggini-Tenzer A, Vuong V, Messikommer A, Nytko KJ, Guckenberger M, Bachmann F, Lane HA, Pruschy M.

Radiother Oncol. 2017 Sep;124(3):433-438. doi: 10.1016/j.radonc.2017.07.024. Epub 2017 Aug 7.

PMID:
28797699
44.

Preserving the legacy of reirradiation: A narrative review of historical publications.

Nieder C, Langendijk JA, Guckenberger M, Grosu AL.

Adv Radiat Oncol. 2017 Feb 28;2(2):176-182. doi: 10.1016/j.adro.2017.02.005. eCollection 2017 Apr-Jun. Review.

45.

Interobserver variability in target volume delineation of hepatocellular carcinoma : An analysis of the working group "Stereotactic Radiotherapy" of the German Society for Radiation Oncology (DEGRO).

Gkika E, Tanadini-Lang S, Kirste S, Holzner PA, Neeff HP, Rischke HC, Reese T, Lohaus F, Duma MN, Dieckmann K, Semrau R, Stockinger M, Imhoff D, Kremers N, Häfner MF, Andratschke N, Nestle U, Grosu AL, Guckenberger M, Brunner TB.

Strahlenther Onkol. 2017 Oct;193(10):823-830. doi: 10.1007/s00066-017-1177-y. Epub 2017 Jul 10.

PMID:
28695316
46.

ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer.

Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, Tanadini-Lang S, Lartigau E, Méndez Romero A, Senan S, Verellen D.

Radiother Oncol. 2017 Jul;124(1):11-17. doi: 10.1016/j.radonc.2017.05.012. Epub 2017 Jul 4.

PMID:
28687397
47.

European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer.

De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, Belderbos J, Guckenberger M, Senan S; Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC).

Radiother Oncol. 2017 Jul;124(1):1-10. doi: 10.1016/j.radonc.2017.06.003. Epub 2017 Jun 27.

PMID:
28666551
48.

ITV, mid-ventilation, gating or couch tracking - A comparison of respiratory motion-management techniques based on 4D dose calculations.

Ehrbar S, Jöhl A, Tartas A, Stark LS, Riesterer O, Klöck S, Guckenberger M, Tanadini-Lang S.

Radiother Oncol. 2017 Jul;124(1):80-88. doi: 10.1016/j.radonc.2017.05.016. Epub 2017 Jun 3.

PMID:
28587761
49.

Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.

Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C, Alheit H, Blank H, Nestle U, Wiehle R, Kornhuber C, Ostheimer C, Petersen C, Pollul G, Baus W, Altenstein G, Beckers E, Jurianz K, Sterzing F, Kretschmer M, Seegenschmiedt H, Maass T, Droege S, Wolf U, Schoeffler J, Haverkamp U, Eich HT, Guckenberger M.

Strahlenther Onkol. 2017 Oct;193(10):780-790. doi: 10.1007/s00066-017-1151-8. Epub 2017 May 31.

PMID:
28567503
50.

[Local consolidative therapy improves progression-free survival in patients with oligometastatic NSCLC : Results of a randomized phase II study].

Finazzi T, Guckenberger M.

Strahlenther Onkol. 2017 Jul;193(7):595-597. doi: 10.1007/s00066-017-1147-4. German. No abstract available.

PMID:
28516198

Supplemental Content

Loading ...
Support Center